Erlotinib is a TKI capable of inhibiting EGFR, and patients with NSCLC show tumour response, survival and tumour‐related symptom improvement,22, 23 whereas its efficacy is limited by inevitable drug resistance developed in long‐term treatment.10, 24. This evidence concerns the gene EGFR and non-small cell lung carcinoma.